相关实验视频
Updated: Jun 5, 2025

02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
5.2K
C2230,一种优先使用和状态依赖的CaV2.2通道阻断剂,可以在多种疼痛模型中减轻疼痛行为
Cheng Tang1,2,3, Kimberly Gomez4, Yan Chen3
1Department of Molecular Pathobiology, College of Dentistry, and.
The Journal of clinical investigation
|December 10, 2024
概括
一种新的CaV2.2抑制剂C2230通过选择性抑制N型通道,为慢性疼痛管理提供了一种新的方法. 这种化合物有望开发出更安全,更有效的止痛药,副作用更少.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学 是一个学科.
- 疼痛研究 疼痛研究
背景情况:
- 目前的CaV2.2 (N型) 通道阻断剂,如Ziconotide和Gabapentin,具有包括狭窄的治疗窗口,不良影响和滥用潜力的局限性.
- 需要针对CaV2.2的新型疼痛疗法,以提高安全性和有效性.
研究的目的:
- 为了识别和描述CaV2.2 (N型) 通道的新型阻塞剂,以潜在的止痛药开发.
- 为了研究一种新发现的CaV2.2抑制剂的作用机制和治疗潜力,C2230.
主要方法:
- 电生理学记录以评估CaV2.2通道活性和C2230的抑制.
- 在体外研究中,使用来自包括人类在内的各种物种的背部根和三角节神经元.
- 在动物模型中进行的神经病变性,口腔面部和骨关节炎疼痛的体内行为研究.
- 针对位点的突变分析,以确定C2230.0的结合位点.
主要成果:
- 鉴定出C2230是一种强大的CaV2.2阻塞剂,可以稳定失活的通道并加速开放状态的失活,表现出使用依赖的抑制.
- C2230在多个物种的神经元中选择性地抑制了CaV2.2,而不影响其他离子通道,运动或心血管功能.
- 在慢性疼痛的各种动物模型中,C2230的使用减少了疼痛行为,包括神经病,口腔面部和骨关节炎疼痛.
- 与现有的CaV2.2抑制剂相比,C2230表现出一种独特的结合机制.
结论:
- C2230代表了一种有前途的化合物,用于开发针对CaV2.2.2.的新型止痛药.
- C2230独特的作用机制和良好的安全性概况表明,它有可能改善慢性疼痛管理.
- 对C2230的进一步研究可能会导致开发更安全,更有效的疼痛治疗药物,并减少副作用和滥用潜力.
相关概念视频
Analgesia and Pain Management
504
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
504
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
455
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
455
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Antihypertensive Drugs: Action of Calcium Channel Blockers
458
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
458

